Soleno Therapeutics (SLNO) Gains from Investment Securities: 2013-2019
Historic Gains from Investment Securities for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2019 value amounting to $7.9 million.
- Soleno Therapeutics' Gains from Investment Securities rose 481.17% to $7.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $7.0 million, marking a year-over-year increase of 351.33%. This contributed to the annual value of $2.8 million for FY2024, which is 374.87% up from last year.
- According to the latest figures from Q4 2019, Soleno Therapeutics' Gains from Investment Securities is $7.9 million, which was up 210.93% from -$7.1 million recorded in Q3 2019.
- Soleno Therapeutics' 5-year Gains from Investment Securities high stood at $7.9 million for Q4 2019, and its period low was -$7.1 million during Q3 2019.
- For the 3-year period, Soleno Therapeutics' Gains from Investment Securities averaged around $866,700, with its median value being $290,500 (2017).
- Examining YoY changes over the last 5 years, Soleno Therapeutics' Gains from Investment Securities showed a top increase of 3,476.92% in 2018 and a maximum decrease of 522.65% in 2018.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Gains from Investment Securities stood at $515,860 in 2015, then tumbled by 432.67% to -$1.7 million in 2016, then spiked by 128.55% to $490,000 in 2017, then crashed by 522.65% to -$2.1 million in 2018, then spiked by 481.17% to $7.9 million in 2019.
- Its Gains from Investment Securities was $7.9 million in Q4 2019, compared to -$7.1 million in Q3 2019 and $4.3 million in Q2 2019.